Skip to main content

Roche Gets FDA OK for New Hepatitis C Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche today said that it has received US Food and Drug Administration clearance for the second-generation version its real-time PCR Cobas TaqMan HCV Test.

The test quantifies the amount of hepatitis C viral RNA in human plasma or serum of HCV-infected individuals. It incorporates a manual specimen preparation with Roche's Cobas TaqMan 48 Analyzer for automated amplification and detection.

Teresa Wright, chief medical officer of Roche Molecular Diagnostics, said in a statement that the test "is key to measuring the effectiveness of many antivirals that are currently in clinical development for the treatment of hepatitis C."

Last month, the FDA cleared for marketing Roche's second-generation Cobas AmpliPrep/Cobas TaqMan HBV Test for quantitative detection of hepatitis B virus DNA in human plasma or serum for patients on hepatitis B virus antiviral therapy.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.